Urethritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
*All patients must be retested 3 months after treatment to evaluate the risk of resistance | *All patients must be retested 3 months after treatment to evaluate the risk of resistance | ||
*Prophylactic ocular antimicrobial medication is strongly recommended for all newborns exposed to [[Neisseria gonorrhoeae]] during birth | *Prophylactic ocular antimicrobial medication is strongly recommended for all newborns exposed to [[Neisseria gonorrhoeae]] during birth | ||
*Gonorrhea and chlamydia are reportable diseases per the CDC, and practitioners should contact their local state health department<ref>{{cite book |last = Bennett |first = John |title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases |publisher = Elsevier/Saunders |location = Philadelphia, PA |year = 2015 |isbn=9781455748013}}</ref><ref name="pmid26042815">{{cite journal |vauthors=Workowski KA, Bolan GA |title=Sexually transmitted diseases treatment guidelines, 2015 |journal=MMWR Recomm Rep |volume=64 |issue=RR-03 |pages=1–137 |year=2015 |pmid=26042815 |doi= |url=}}</ref><ref name="pmid20353145">{{cite journal |vauthors=Brill JR |title=Diagnosis and treatment of urethritis in men |journal=Am Fam Physician |volume=81 |issue=7 |pages=873–8 |year=2010 |pmid=20353145 |doi= |url=}}</ref> | *Gonorrhea and chlamydia are reportable diseases per the CDC, and practitioners should contact their local state health department.<ref>{{cite book |last = Bennett |first = John |title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases |publisher = Elsevier/Saunders |location = Philadelphia, PA |year = 2015 |isbn=9781455748013}}</ref><ref name="pmid26042815">{{cite journal |vauthors=Workowski KA, Bolan GA |title=Sexually transmitted diseases treatment guidelines, 2015 |journal=MMWR Recomm Rep |volume=64 |issue=RR-03 |pages=1–137 |year=2015 |pmid=26042815 |doi= |url=}}</ref><ref name="pmid20353145">{{cite journal |vauthors=Brill JR |title=Diagnosis and treatment of urethritis in men |journal=Am Fam Physician |volume=81 |issue=7 |pages=873–8 |year=2010 |pmid=20353145 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 16:01, 4 October 2016
|
Urethritis Microchapters | |
|
Diagnosis | |
|
Treatment | |
|
Case Studies | |
|
Urethritis secondary prevention On the Web | |
|
American Roentgen Ray Society Images of Urethritis secondary prevention | |
|
Risk calculators and risk factors for Urethritis secondary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
In order to prevent transmission to partner and decrease the risk of antibiotic resistance all patients must be instructed for safe sex practicing and screening after treatment.
Secondary Prevention
- Patients should be instructed in safe sex practice.
- All sex partners within the last 60 days must be evaluated for possible urethritis.
- Patients should be screened for other sexually transmitted diseases e.g. HIV and syphilis.
- All patients must be retested 3 months after treatment to evaluate the risk of resistance
- Prophylactic ocular antimicrobial medication is strongly recommended for all newborns exposed to Neisseria gonorrhoeae during birth
- Gonorrhea and chlamydia are reportable diseases per the CDC, and practitioners should contact their local state health department.[1][2][3]
References
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 9781455748013.
- ↑ Workowski KA, Bolan GA (2015). "Sexually transmitted diseases treatment guidelines, 2015". MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.
- ↑ Brill JR (2010). "Diagnosis and treatment of urethritis in men". Am Fam Physician. 81 (7): 873–8. PMID 20353145.